Mobile website
Clinical Research
Changes and significance of peripheral blood PD-1 level and related immune indicators during radiochemotherapy in patients with nasopharyngeal carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To detect the expression of programmed death molecule 1 (PD-1) on T cell surface, the levels of T cell subsets and other immune indices in patients with nasopharyngeal carcinoma (NPC) during chemoradiotherapy, and to discuss the immune function of patients in different treatment periods. Methods: Blood samples of 30 patients who were pathologically confirmed of nasopharyngeal carcinoma in Fujian Cancer Hospital from April 2015 to September 2015 were collected for this study. Flow cytometry was used to dynamically detect the immune indicators of NPC patients in different treatment periods (pre-treatment, post-chemotherapy and post-radiotherapy), including PD-1 on T cell surface, T cell subsets, NK cells and B cells etc. Results: Compared with pre[1]treatment, the proportion of CD3+ T cells, CD4+T cells, CD8+CD28+T cells and CD4+/CD8+ ratio in peripheral blood of patients increased significantly, while the proportion of B cells (CD19+) and NK cells (CD3-CD16+CD56+ cells) decreased significantly after neoadjuvant chemotherapy (all P<0.05). After chemoradiotherapy, the proportion of CD4+T cells, CD8+CD28+T cells and CD4+/CD8+ ratio in peripheral blood of patients decreased to a lower level compared to pre-treatment (all P<0.05), while the proportion of NK cells was up-regulated (P<0.05). Compared with pre-treatment, the expression level of PD-1 on T cells increased significantly after radiotherapy (P<0.05). Conclusion: The study found that the proportion of T cell subsets in peripheral blood increased after neoadjuvant chemotherapy but decreased significantly at the end of radiotherapy, indicating that the immune function of NPC patients was significantly suppressed at the end of radiotherapy. The expression level of PD-1 on T cells was significantly up-regulated after radiotherapy, indicating that the end of chemoradiotherapy maybe an optimal timepoint for anti-PD-1 immunotherapy, which may exert more efficient and long-lasting anti-tumor effect for NPC.
Keywords:
Project Supported:
Project supported by the the Natural Science Foundation of Fujian Province (No. 2015J01380), and the Qihang Foundation of Fujian Medical University (No. 2019QH1193)
Clc Number:
